Stephan Grupp
Overview
Explore the profile of Stephan Grupp including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
1466
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Grzywa T, Mehta N, Cossette B, Romanov A, Paruzzo L, Ramasubramanian R, et al.
bioRxiv
. 2024 Apr;
PMID: 38659938
Chimeric antigen receptor (CAR) T cell therapy targeting CD19 elicits remarkable clinical efficacy in B-cell malignancies, but many patients relapse due to failed expansion and/or progressive loss of CAR-T cells....
2.
Locatelli F, Lang P, Wall D, Meisel R, Corbacioglu S, Li A, et al.
N Engl J Med
. 2024 Apr;
390(18):1663-1676.
PMID: 38657265
Background: Exagamglogene autotemcel (exa-cel) is a nonviral cell therapy designed to reactivate fetal hemoglobin synthesis through ex vivo clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 gene editing of the erythroid-specific...
3.
Schuelke M, Bassiri H, Behrens E, Canna S, Croy C, DiNofia A, et al.
Blood Adv
. 2023 Sep;
7(18):5603-5607.
PMID: 37721859
No abstract available.
4.
Elgarten C, Wohlschlaeger A, Levy E, Tadley K, Wang L, Atkinson M, et al.
Transplant Cell Ther
. 2023 Jul;
29(10):635.e1-635.e8.
PMID: 37517611
Revaccination after hematopoietic cell transplantation (HCT) is critical to prevent morbidity and mortality from vaccine-preventable illnesses. The global aim of our quality improvement initiative was to enhance timely, correct, and...
5.
Al Malki M, London K, Baez J, Akahoshi Y, Hogan W, Etra A, et al.
Blood Adv
. 2023 May;
7(17):5189-5198.
PMID: 37235690
Graft-versus-host disease (GVHD) of the gastrointestinal (GI) tract is the main cause of nonrelapse mortality (NRM) after allogeneic hematopoietic cell transplantation. Ann Arbor (AA) scores derived from serum biomarkers at...
6.
Zewde M, Morales G, Gandhi I, Ozbek U, Aguayo-Hiraldo P, Ayuk F, et al.
Transplant Cell Ther
. 2021 Sep;
27(12):988.e1-988.e7.
PMID: 34474163
Acute graft-versus-host disease (GVHD) is a major cause of mortality in patients undergoing hematopoietic cell transplantation (HCT) for hematologic malignancies. The skin is the most commonly involved organ in GVHD....
7.
Kasikis S, Baez J, Gandhi I, Grupp S, Kitko C, Kowalyk S, et al.
Bone Marrow Transplant
. 2021 Sep;
56(11):2869-2870.
PMID: 34471240
No abstract available.
8.
Weiss B, Yanik G, Naranjo A, Zhang F, Fitzgerald W, Shulkin B, et al.
Pediatr Blood Cancer
. 2021 May;
68(10):e29117.
PMID: 34028986
Introduction: I-meta-iodobenzylguanidine ( I-MIBG) is effective in relapsed neuroblastoma. The Children's Oncology Group (COG) conducted a pilot study (NCT01175356) to assess tolerability and feasibility of induction chemotherapy followed by I...
9.
Frangoul H, Altshuler D, Cappellini M, Chen Y, Domm J, Eustace B, et al.
N Engl J Med
. 2020 Dec;
384(3):252-260.
PMID: 33283989
Transfusion-dependent β-thalassemia (TDT) and sickle cell disease (SCD) are severe monogenic diseases with severe and potentially life-threatening manifestations. BCL11A is a transcription factor that represses γ-globin expression and fetal hemoglobin...
10.
Pasquini M, Hu Z, Curran K, Laetsch T, Locke F, Rouce R, et al.
Blood Adv
. 2020 Nov;
4(21):5414-5424.
PMID: 33147337
Tisagenlecleucel is a CD19 chimeric antigen receptor (CAR) T-cell therapy approved for treatment of pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia (ALL) and adults with non-Hodgkin lymphoma...